vs
滨特尔（PNR）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
滨特尔的季度营收约是Royalty Pharma plc的1.7倍（$1.0B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 16.6%，领先17.8%），Royalty Pharma plc同比增速更快（4.8% vs 2.6%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -2.9%）
滨特尔（股票代码PNR）是知名水处理企业，注册地位于爱尔兰，税务居民身份归属英国，美国区总部设于明尼苏达州金谷市。品牌起源于美国，2017年数据显示其65%的营收来自美国和加拿大，2014年集团完成架构重组，注册地由瑞士变更为爱尔兰。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
PNR vs RPRX — 直观对比
营收规模更大
PNR
是对方的1.7倍
$622.0M
营收增速更快
RPRX
高出2.2%
2.6%
净利率更高
RPRX
高出17.8%
16.6%
两年增速更快
RPRX
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $622.0M |
| 净利润 | $172.4M | $214.2M |
| 毛利率 | 41.8% | — |
| 营业利润率 | 20.3% | 62.4% |
| 净利率 | 16.6% | 34.4% |
| 营收同比 | 2.6% | 4.8% |
| 净利润同比 | 11.3% | 2.9% |
| 每股收益（稀释后） | — | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PNRRPRX
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $1.1B | $578.7M | ||
| Q1 25 | $1.0B | $568.2M | ||
| Q4 24 | $972.9M | $593.6M | ||
| Q3 24 | $993.4M | $564.7M | ||
| Q2 24 | $1.1B | $537.3M |
净利润PNRRPRX
| Q1 26 | $172.4M | — | ||
| Q4 25 | $166.1M | $214.2M | ||
| Q3 25 | $184.3M | $288.2M | ||
| Q2 25 | $148.5M | $30.2M | ||
| Q1 25 | $154.9M | $238.3M | ||
| Q4 24 | $166.4M | $208.2M | ||
| Q3 24 | $139.6M | $544.0M | ||
| Q2 24 | $186.1M | $102.0M |
毛利率PNRRPRX
| Q1 26 | 41.8% | — | ||
| Q4 25 | 40.4% | — | ||
| Q3 25 | 41.0% | — | ||
| Q2 25 | 40.7% | — | ||
| Q1 25 | 39.9% | — | ||
| Q4 24 | 38.8% | — | ||
| Q3 24 | 39.6% | — | ||
| Q2 24 | 39.8% | — |
营业利润率PNRRPRX
| Q1 26 | 20.3% | — | ||
| Q4 25 | 20.1% | 62.4% | ||
| Q3 25 | 22.7% | 70.1% | ||
| Q2 25 | 19.4% | 36.3% | ||
| Q1 25 | 20.1% | 94.0% | ||
| Q4 24 | 20.1% | 60.9% | ||
| Q3 24 | 18.1% | — | ||
| Q2 24 | 22.6% | 50.2% |
净利率PNRRPRX
| Q1 26 | 16.6% | — | ||
| Q4 25 | 16.3% | 34.4% | ||
| Q3 25 | 18.0% | 47.3% | ||
| Q2 25 | 13.2% | 5.2% | ||
| Q1 25 | 15.3% | 41.9% | ||
| Q4 24 | 17.1% | 35.1% | ||
| Q3 24 | 14.1% | 96.3% | ||
| Q2 24 | 16.9% | 19.0% |
每股收益（稀释后）PNRRPRX
| Q1 26 | — | — | ||
| Q4 25 | $1.01 | $0.49 | ||
| Q3 25 | $1.12 | $0.67 | ||
| Q2 25 | $0.90 | $0.07 | ||
| Q1 25 | $0.93 | $0.55 | ||
| Q4 24 | $0.99 | $0.46 | ||
| Q3 24 | $0.84 | $1.21 | ||
| Q2 24 | $1.11 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $67.7M | $618.7M |
| 总债务越低越好 | $1.9B | $9.0B |
| 股东权益账面价值 | $3.8B | $9.7B |
| 总资产 | $7.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.51× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资PNRRPRX
| Q1 26 | $67.7M | — | ||
| Q4 25 | — | $618.7M | ||
| Q3 25 | $128.4M | $938.9M | ||
| Q2 25 | $143.0M | $631.9M | ||
| Q1 25 | $140.6M | $1.1B | ||
| Q4 24 | $118.7M | $929.0M | ||
| Q3 24 | $218.1M | $950.1M | ||
| Q2 24 | $214.3M | $1.8B |
总债务PNRRPRX
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.6B | $9.0B | ||
| Q3 25 | $1.6B | $8.9B | ||
| Q2 25 | $1.4B | $8.0B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.6B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | $1.8B | $7.6B |
股东权益PNRRPRX
| Q1 26 | $3.8B | — | ||
| Q4 25 | $3.9B | $9.7B | ||
| Q3 25 | $3.8B | $9.6B | ||
| Q2 25 | $3.7B | $9.5B | ||
| Q1 25 | $3.6B | $9.8B | ||
| Q4 24 | $3.6B | $10.3B | ||
| Q3 24 | $3.5B | $10.3B | ||
| Q2 24 | $3.4B | $9.8B |
总资产PNRRPRX
| Q1 26 | $7.1B | — | ||
| Q4 25 | $6.9B | $19.6B | ||
| Q3 25 | $6.8B | $19.3B | ||
| Q2 25 | $6.5B | $18.3B | ||
| Q1 25 | $6.7B | $17.6B | ||
| Q4 24 | $6.4B | $18.2B | ||
| Q3 24 | $6.5B | $18.0B | ||
| Q2 24 | $6.5B | $17.7B |
负债/权益比PNRRPRX
| Q1 26 | 0.51× | — | ||
| Q4 25 | 0.42× | 0.92× | ||
| Q3 25 | 0.42× | 0.93× | ||
| Q2 25 | 0.38× | 0.84× | ||
| Q1 25 | 0.51× | 0.78× | ||
| Q4 24 | 0.46× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | 0.51× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $-85.7M | — |
| 自由现金流率自由现金流/营收 | -8.3% | — |
| 资本支出强度资本支出/营收 | 1.8% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $716.0M | — |
8季度趋势，按日历期对齐
经营现金流PNRRPRX
| Q1 26 | — | — | ||
| Q4 25 | $50.8M | $827.1M | ||
| Q3 25 | $196.3M | $702.6M | ||
| Q2 25 | $606.6M | $364.0M | ||
| Q1 25 | $-38.9M | $596.1M | ||
| Q4 24 | $86.5M | $742.5M | ||
| Q3 24 | $248.6M | $703.6M | ||
| Q2 24 | $539.2M | $658.2M |
自由现金流PNRRPRX
| Q1 26 | $-85.7M | — | ||
| Q4 25 | $27.1M | — | ||
| Q3 25 | $178.9M | — | ||
| Q2 25 | $595.7M | — | ||
| Q1 25 | $-55.7M | — | ||
| Q4 24 | $63.8M | — | ||
| Q3 24 | $233.2M | — | ||
| Q2 24 | $522.2M | — |
自由现金流率PNRRPRX
| Q1 26 | -8.3% | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 17.5% | — | ||
| Q2 25 | 53.0% | — | ||
| Q1 25 | -5.5% | — | ||
| Q4 24 | 6.6% | — | ||
| Q3 24 | 23.5% | — | ||
| Q2 24 | 47.5% | — |
资本支出强度PNRRPRX
| Q1 26 | 1.8% | — | ||
| Q4 25 | 2.3% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.5% | — |
现金转化率PNRRPRX
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | 3.86× | ||
| Q3 25 | 1.07× | 2.44× | ||
| Q2 25 | 4.08× | 12.06× | ||
| Q1 25 | -0.25× | 2.50× | ||
| Q4 24 | 0.52× | 3.57× | ||
| Q3 24 | 1.78× | 1.29× | ||
| Q2 24 | 2.90× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PNR
| Water Solutions | $391.0M | 38% |
| Pool | $387.1M | 37% |
| Flow | $258.1M | 25% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
